市場調査レポート - 213737

新しいドラッグデリバリー(薬物送達)技術および戦略:企業・パイプライン・提携

Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships

発行 Espicom Business Intelligence
出版日 ページ情報 英文 188 Pages
価格
新しいドラッグデリバリー(薬物送達)技術および戦略:企業・パイプライン・提携 Emerging Drug Delivery Technologies & Strategies - Players, Pipelines & Partnerships
出版日: 2011年09月12日 ページ情報: 英文 188 Pages
概要

当レポートでは、3種の主要ドラッグデリバリー(薬物送達)技術部門の主要動向について調査分析し、各種ドラッグデリバリー技術の概要、主要アプリケーションエリア、現在利用可能な製品の概要と製品開発動向、主要製品の売上予測(〜2020年)、主なスペシャリストディベロッパーの分析などをまとめ、概略下記の構成でお届けいたします。

第1巻 脂質ベースのデリバリー技術

  • エグゼクティブサマリー
  • イントロダクション
    • 脂質ベースのデリバリープラットフォームの各種タイプ
  • ドラッグデリバリー(薬物送達)のアプリケーションと製品開発
    • 経口 & 舌下
    • 非経口
    • 肺投与/鼻腔投与
    • 経皮/局所
  • デリバリープロファイル
    • ナノデリバリー
    • コントロールドデリバリー
    • 標的デリバリー
  • 各種治療分野への適用
    • 感染疾患
    • CNS & 疼痛
    • 呼吸器系
    • 心臓
    • 眼球
    • その他
  • 主要20社のプロファイル
  • 有望な脂質ベースのドラッグデリバリー(薬物送達)スペシャリスト
  • 総論

第2巻:ポリマーベースのデリバリー技術

  • エグゼクティブサマリー
  • イントロダクション
  • ポリマーベースのデリバリープラットフォームの各種タイプ
  • ドラッグデリバリー(薬物送達)のアプリケーションと製品開発
    • 経口 & 舌下
    • 非経口
    • 経皮
  • デリバリー動向
    • ナノデリバリー
    • コントロールドデリバリー
    • 標的デリバリー
  • 治療動向
    • 神経病 & 疼痛
    • 心臓病
    • 胃腸疾患
    • 代謝障害
    • その他
  • 主要20社のプロファイル
  • ENDO PHARMACEUTICALS
  • 有望な脂質ベースのドラッグデリバリー(薬物送達)スペシャリスト
  • 見通し

第3巻 バイオベクター:遺伝子治療薬/RNA治療薬/ワクチン

  • エグゼクティブサマリー
  • イントロダクション
  • バイオベクターの各種タイプ
    • ウィルスベクター
      • アデノ随伴ウイルスベクター
      • アデノウイルスベクター
      • アルファウイルスベクター
      • レンチウイルスベクター
      • ポックスウイルスベクター
      • その他のウイルスベクター
    • 非ウィルスベクター
      • バクテリア
      • 酵母
      • 高度ドラッグデリバリー(薬物送達)システム
      • 脂質ベースのデリバリー
      • ポリマーベースのデリバリー
      • デリバリーデバイス
  • 遺伝子治療薬・RNAi治療薬・ワクチンの開発とアプリケーション
  • デリバリー動向
  • 治療動向
  • 主要20社のプロファイル
  • 遺伝子治療薬のデリバリー
  • RNA治療薬のスペシャリスト
  • ワクチンデリバリーのスペシャリスト
  • 有望な脂質ベースの遺伝子治療薬・RNAi治療薬・ワクチンデリバリーのスペシャリスト
  • 見通し
目次

Abstract

  • examination of trends and advances in the three major drug delivery sectors
  • Unique sales forecasts to 2020 for key products
  • Critical analyses of 58 specialist developers driving the drug delivery market onwards

Increasingly, pharmaceutical companies are turning to drug delivery developers to overcome a range of challenges in getting novel new medicines and formulations effectively and safely delivered. Indeed, it can be argued that identifying an efficient delivery method is as important as the therapy itself. This new report assesses three key emerging sectors in the drug delivery field that will play a crucial role in tackling a range of delivery issues associated with these new classes of drugs in key therapeutic areas such as cancer, CNS, cardiology, respiratory and ophthalmology.

This report provides a detailed insight into the current and future market and...

  • Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed
  • Identifies key application areas
  • Appraises currently available products which utilise advanced delivery platforms
  • Examines new product developments from major specialist drug delivery companies, critically analysing their prospects
  • Allows ready comparison on different technologies within a company' s portfolio.

Use this report to...

  • Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies
  • Identify and review licensing and collaborative partners
  • Understand the merits and applications of the main approaches being researched.

‘...A complete analysis packed with market facts, sector forecasts to 2020 and detailed company evaluations...’

Lipid-based delivery

Many new chemical entities are poorly water soluble which may affect a drug' s bioavailability and efficacy. Advanced drug delivery systems using biocompatible lipid-based technologies can be used to improve solubility, increase bioavailability (enhance absorption) and efficacy, helping to reduce the level of drug dosage and decrease the incidence and severity of adverse effects.

To date more than a dozen products have been approved that utilise some of the first generation lipid-based technologies, pioneered by Elan Pharmaceuticals, Enzon, Gilead Pharmaceuticals, ALZA (acquired by Johnson & Johnson), Skye Pharma, and The Liposome Company (acquired by Elan Pharmaceuticals). These products encompass anaesthetics, antiinfectives and oncology agents and together generate over US$1.85 billion in sales annually.

Research activity is intensive and the top 20 drug delivery specialists are currently investigating more than 75 products in preclinical and clinical development; over half of these products (c.46 products) are likely to reach the market by 2020 to generate global sales in excess of US$2.6 billion by 2020.

Questions answered

  • What are the competing technologies to Lipocine' s Lip' ral?
  • Which products in research exploit Aradigm' s proprietary inhalable drug technology?
  • Who is bank-rolling NanoBio' s R&D programme?
  • Tekmira has 6 potential product launches coming up - what are the sales forecasts to 2020?
  • What research is being undertaken with lipid-based platforms for the delivery of targeted products?

Polymer-based delivery

The pharmaceutical industry has been utilising advanced polymer-based delivery technologies to improve the pharmacokinetics and targeted delivery of small and large molecule drugs.

To date more than two dozen products have been approved that utilise PEGylation technologies developed by some of the industry pioneers, such as ALZA, Endo Pharmaceuticals and Nektar Therapeutics. In addition, several specialists have developed controlled-release polymer matrix to prolong the release of active pharmaceutical ingredients in situ with technologies developed by Debiopharm Group and Durect.

By 2020 we forecast that nearly 60 novel polymer-based products could reach the market to generate global sales in excess of US$5 billion through improved pharmacokinetics of approved and new compounds, as well as the emergence of novel biologics, nucleic acidbased medicines and small molecule agents.

Questions answered

  • Which companies are working in the colonic drug delivery area?
  • Which company acquired Biocompatibles International to gain access to the polymer-based bead technology sector?
  • How important will the urological treatment Urocidin be to Endo Pharmaceutical' s financial health?
  • What opportunities are there in polymer-based transdermal delivery?

Biovectors/Gene Therapy/Vaccines

During the last twenty years there have been significant advances in the manufacture, development and delivery of gene therapies, RNA therapies and vaccines. No single biovector stands out for each field and many different development strategies have been adopted to optimise delivery.

Gene-related medicines have achieved limited success to date - no gene therapies have been approved and only a few antisense drugs have carved out a therapeutic niche in ocular diseases (Vitravene; CMV, Macugen; wet AMD). However, R&D investment for gene related products continues to grow at a fast rate and this highlights the challenges and opportunities which face developers, delivery technologists and regulators in this field.

In contrast, interest in the vaccine market has rocketed fuelled by biodefence programmes and the outbreak of avian influenza as well as advances in vaccine production technologies which has lowered the barrier to entry for the smaller players. Whilst infectious diseases, particularly influenza and HIV, remain a major area of interest, therapeutic vaccines are emerging to gain a share of the marketplace.

Questions answered

  • Which product sector is set to exceed sales of US$2 billion by 2020?
  • Which company commenced Phase II trials in January 2011 for a DNA vaccine to treat leukaemia?
  • Which company has AtuRNAi products in Phase II development for Macular Oedema and Agerelated Macular Degeneration?
  • 10 companies are active in the field of oncology. Who are they and what is their pipeline?

Figure 1:
Impact of aqueous solubility and membrane permeability of choice of advanced delivery system

Source: modified from David J Hauss, Bristol-Myers Squibb' s presentation entitled “Lipid-based systems for oral drug delivery.”

Table of Contents

Volume 1 - Lipid-based delivery technologies

ABOUT THE AUTHOR

  • Dr. Cheryl L Barton

EXECUTIVE SUMMARY

INTRODUCTION

  • Types of lipid-based delivery platforms

APPLICATIONS IN DRUG DISCOVERY AND PRODUCT DEVELOPMENT

  • Oral & buccal
  • Parenteral
  • Pulmonary/Intranasal
  • Transdermal/Topical

DELIVERY PROFILES

  • Nano-enabled delivery
  • Controlled delivery
  • Targeted delivery

APPLICATIONS IN DIFFERENT THERAPEUTIC AREAS

  • Oncology
  • Infectious diseases
  • CNS & Pain
  • Respiratory
  • Cardiology
  • Ocular
  • Other

TOP 20 COMPANY PROFILES

  • AlphaRx Corporation
  • Aphios Corporation
  • Aradigm Corporation
  • Axentis Pharma AG
  • Azaya Therapeutics
  • Bio-Path Holdings
  • Camurus AB
  • Celsion Corporation
  • Clavis Pharma ASA
  • Cornerstone Pharmaceuticals
  • Insys Therapeutics
  • Latitude Pharmaceuticals
  • Lipocine
  • Marina Biotech
  • Merrimack Pharmaceuticals
  • NanoBio Corporation
  • Novagali Pharma SA
  • Talon Therapeutics
  • Taiwan Liposome Company
  • Tekmira Pharmaceuticals Corporation

UP & COMING LIPID-BAS ED DRUG DELIVERY SPECIALISTS

CONCLUSIONS

BIBLIOGRAPHY & ENDNOTES

Volume 2 - Polymer-based delivery technologies

EXECUTIVE SUMMARY

INTRODUCTION

TYPES OF POLYMER-BAS ED DELIVERY PLATFORMS

APPLICATIONS IN DRUG DISCOVERY AND PRODUCT DEVELOPMENT

  • Oral & buccal
  • Parenteral
  • Transdermal

DELIVERY TRENDS

  • Nano-enabled delivery
  • Controlled delivery
  • Targeted delivery

THERAPEUTIC TRENDS

  • Oncology
  • Neurology & Pain
  • Cardiology
  • Gastroenterology
  • Metabolic
  • Other

TOP 20 COMPANY PROFILES

  • Access Pharmaceuticals
  • Alkermes
  • BioDelivery Sciences International
  • BTG International
  • Calando Pharmaceuticals
  • Debiopharm Group
  • Durect Corporation
  • Expression Genetics

ENDO PHARMACEUTICALS

  • Enzon Pharmaceuticals
  • Labopharm
  • Mersana Therapeutics
  • Mountain View Pharmaceuticals
  • Nanocarrier
  • Nektar Therapeutics
  • OctoPlus N.V
  • Samyang Pharmaceuticals
  • Supratek Pharma
  • SurModics
  • Teikoku Pharma USA

UP & COMING POLYMER-BASED DRUG DELIVERY SPECIALISTS

OUTLOOK

BIBLIOGRAPHY & ENDNOTES

Volume 3 - Biovectors: Gene Therapies/RNA Therapeutics/Vaccines

EXECUTIVE SUMMARY

INTRODUCTION

TYPES OF BIOVECTORS

  • Viral vectors
    • Adeno-associated virus vectors
    • Adenovirus vectors
    • Alphavirus vectors
    • Lentivirus vectors
    • Poxvirus vectors
    • Other viral vectors
  • Non-viral vectors
    • Bacteria
    • Yeast
    • Advanced drug delivery systems
    • Lipid-based delivery
    • Polymeric-based delivery
    • Delivery devices

APPLICATIONS IN THE DEVELOPMENT OF GENE THERAPIES, RNAI THERAPEUTICS AND VACCINES

DELIVERY TRENDS

  • Gene Therapies
  • RNA Therapeutics
  • Vaccines

THERAPEUTIC TRENDS

  • Gene Therapies
  • RNA Therapeutics
  • Vaccines

TOP 20 COMPANY PROFILES

  • Gene Therapies
  • RNA Therapeutics
  • Vaccines

GENE THERAPY DELIVERY

  • Ark Therapeutics
  • Ceregene
  • Expression Genetics
  • Neurologix
  • Oxford BioMedica

RNA THERAPEUTIC DELIVERY SPECIALISTS

  • Alnylam Pharmaceuticals
  • Calando Pharmaceuticals
  • CureVac GmbH
  • Marina Biotech
  • Santaris Pharma A/S
  • Silence Therapeutics
  • Tekmira Pharmaceutical Corporation

VACCINE DELIVERY SPECIALISTS

  • Crucell N.V.
  • GlobeImmune
  • Inovio Pharmaceuticals
  • Ichor Medical Systems
  • Juvaris BioTherapeutics
  • Lipotek Pty
  • Vical
  • VIRxSys

UP & COMING GENE THERAPY, RNAI THERAPEUTICS AND VACCINE DELIVERY SPECIALISTS

OUTLOOK

BIBLIOGRAPHY & ENDNOTES

Back to Top